Thermo Fisher Scientific (NYSE: TMO), the world leader in serving science, is confident in being able to secure all necessary outstanding regulatory and antitrust approvals in connection with its previously announced tender offer to acquire all of the outstanding shares of Dionex Corporation (NASDAQ: DNEX) for $118.50 per share in cash.
Thermo Fisher expects to consummate the tender offer promptly after its expiration, scheduled for 7:00 p.m., New York City time, on Friday, May 13, 2011, subject to receipt of these approvals. Consummation of the tender offer also assumes that at least a majority of the outstanding shares of Dionex common stock, on a fully diluted basis, have been tendered and not withdrawn prior to the expiration of the offer and that other standard closing conditions have been satisfied.
Thermo Fisher Scientific continues to support the development of COVID-19 vaccines, therapies